Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The burden of disease and the need for a simple staging system in idiopathic pulmonary fibrosis.

O'Connell OJ, Egan JJ.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):765-7. doi: 10.1164/rccm.201402-0306ED. No abstract available.

PMID:
24684356
2.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):825-31. doi: 10.1164/rccm.201311-1951OC.

3.

Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.

Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group.

Thorax. 2012 Nov;67(11):938-40. doi: 10.1136/thoraxjnl-2012-202580. Epub 2012 Oct 9. No abstract available.

PMID:
23047830
4.

Importance of idiopathic pulmonary fibrosis staging for clinical trial endpoints.

O'Connell OJ, Riddell P, Egan JJ.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1271. doi: 10.1164/rccm.201208-1555LE. No abstract available.

PMID:
23725620
5.

Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.

Rose DM, Montgomery AB.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1269. doi: 10.1164/rccm.201204-0690LE. No abstract available.

PMID:
23725617
6.

Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time.

Spagnolo P, Luppi F, Maher TM, Wuyts WA, Grutters JC.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1271-2. doi: 10.1164/rccm.201209-1755LE. No abstract available.

PMID:
23725621
7.

Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis.

Bradford WZ, Cohen AH, Leff JA.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1269-70. doi: 10.1164/rccm.201204-0770LE. No abstract available.

PMID:
23725618
8.

Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.

Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1272. doi: 10.1164/rccm.201304-0712LE. No abstract available.

PMID:
23725623
9.

Mortality, a bar too high for idiopathic pulmonary fibrosis clinical trials!

Behr J.

Am J Respir Crit Care Med. 2013 Jun 1;187(11):1270-1. doi: 10.1164/rccm.201205-0926LE. No abstract available.

PMID:
23725619
10.

Design issues in randomized phase II/III trials.

Korn EL, Freidlin B, Abrams JS, Halabi S.

J Clin Oncol. 2012 Feb 20;30(6):667-71. doi: 10.1200/JCO.2011.38.5732. Epub 2012 Jan 23.

11.

Design of randomized controlled trials.

Stanley K.

Circulation. 2007 Mar 6;115(9):1164-9. Review. No abstract available.

12.

General keynote: clinical trial design.

Berry DA.

Gynecol Oncol. 2003 Jan;88(1 Pt 2):S114-6; S122-3. Review. No abstract available.

PMID:
12586099
13.

Evolvement of best practice in diagnosis and management of idiopathic pulmonary fibrosis.

Poletti V.

Eur Respir Rev. 2014 Mar 1;23(131):3-4. doi: 10.1183/09059180.00008713. No abstract available.

14.

Interferon gamma for idiopathic pulmonary fibrosis.

Bouros D.

Lancet. 2009 Jul 18;374(9685):180-2. doi: 10.1016/S0140-6736(09)60689-9. Epub 2009 Jun 29. No abstract available.

PMID:
19570574
15.
16.

Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.

du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW.

Am J Respir Crit Care Med. 2012 Oct 15;186(8):712-5. doi: 10.1164/rccm.201206-1010PP. Epub 2012 Jul 12.

PMID:
22798316
17.

Specific keynote: clinical trial design problems in ovarian cancer.

Stevenson A, Gore M.

Gynecol Oncol. 2003 Jan;88(1 Pt 2):S117-21; discussion S122-3. Review. No abstract available.

PMID:
12586100
18.

Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens.

Howard G, Coffey CS, Cutter GR.

Stroke. 2005 Jul;36(7):1622-3. Epub 2005 Jun 9. No abstract available.

19.

[Phase III trials in oncology].

Imadalou K, Cvitkovic E.

Bull Cancer. 1999 Feb;86(2):143-7. Review. French.

20.

Autologous hematopoietic stem cell transplantation for multiple sclerosis--if confused or hesitant, remember: 'treat with standard immune suppressive drugs and if no inflammation, no response'.

Burt RK, Balabanov R, Voltarelli J, Barreira A, Burman J.

Mult Scler. 2012 Jun;18(6):772-5. doi: 10.1177/1352458512442993. No abstract available.

PMID:
22619224

Supplemental Content

Support Center